Tao Wang

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

Yi‐Long Wu, Ying Cheng, Xiangdong Zhou et al. · The Lancet Oncology · 2017 · 1.2K citations

Oncology, Pathology, Bronchial Neoplasm +9

Exosomal miR-1290 and miR-375 as Prognostic Markers in Castration-resistant Prostate Cancer

Xiaoyi Huang, Tiezheng Yuan, Meihua Liang et al. · European Urology · 2014 · 693 citations · Full text

Prognostic Biomarkers, Urology, Oncology +10

Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and <i>EGFR</i>-Activating Mutations

Tony Mok, Ying Cheng, Xiangdong Zhou et al. · Journal of Clinical Oncology · 2018 · 428 citations

Compared Dacomitinib, Advanced Nsclc, Cancer Epidemiology +13

Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity

Jeremy R. Graff, Bruce W. Konicek, Thomas M. Vincent et al. · Journal of Clinical Investigation · 2007 · 375 citations · Full text

Tumor Biology, Therapeutic Suppression, Medicine +12

Lactation-Related MicroRNA Expression Profiles of Porcine Breast Milk Exosomes

Yiren Gu, Mingzhou Li, Tao Wang et al. · PLoS ONE · 2012 · 252 citations · Full text